Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Diğer sürümleri göster (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Detaylı Bibliyografya
Asıl Yazarlar:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2008

Benzer Materyaller

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
Yazar:: Valéria Coelho Santa Rita Pereira, ve diğerleri
Baskı/Yayın Bilgisi: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
Yazar:: GJ Melendez-Torres, ve diğerleri
Baskı/Yayın Bilgisi: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
Yazar:: E.J. Ramos González, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
Yazar:: N. Y. Lasch
Baskı/Yayın Bilgisi: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
Yazar:: Katarzyna Kapica-Topczewska, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
Yazar:: G. J. Melendez-Torres, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
Yazar:: G. Ya. Shvarts
Baskı/Yayın Bilgisi: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Yazar:: Özlem Taşkapılıoğlu, ve diğerleri
Baskı/Yayın Bilgisi: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Yazar:: Özlem Taşkapılıoğlu, ve diğerleri
Baskı/Yayın Bilgisi: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Yazar:: Oscar Fernández
Baskı/Yayın Bilgisi: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Yazar:: Massimiliano Mirabella, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Yazar:: Mikhail Melnikov, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
Yazar:: Methma Udawatta, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Yazar:: Aaron Boster, ve diğerleri
Baskı/Yayın Bilgisi: (2011-09-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
Yazar:: P Tappenden, ve diğerleri
Baskı/Yayın Bilgisi: (2004-06-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
Yazar:: Anna Gil-Sánchez, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
Yazar:: Arielle Kasindi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
Yazar:: Arthur Komlosh, ve diğerleri
Baskı/Yayın Bilgisi: (2019-07-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
Yazar:: Genaro Gabriel Ortíz, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
Yazar:: Ioana S. Barac, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Yazar:: T. E. Shmidt
Baskı/Yayın Bilgisi: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
Yazar:: Ignacio Casanova, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
Yazar:: Justin M. Honce, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
Yazar:: Lyubomira Vlahova, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
Yazar:: Oliver Neuhaus, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Yazar:: María I. Dominguez-Mozo, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
Yazar:: Afsaneh Shirani, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
Yazar:: Ümmügülsüm Koc, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Yazar:: Fadi Towfic, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Yazar:: Oreja-Guevara Celia, ve diğerleri
Baskı/Yayın Bilgisi: (2012-09-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
Yazar:: Apfel Rainer, ve diğerleri
Baskı/Yayın Bilgisi: (2008-09-01)